FDA APPROVES GUIDANT'S NEW CRT-D, WIRELESS SYSTEM
Medical devicemaker Guidant said the FDA has approved a new implantable defibrillator and a wireless system that can program how the device treats patients.
Guidant's Contak Renewal 3 RF is the company's first wandless cardiac resynchronization therapy defibrillator (CRT-D). When used with the new Zoom Latitude wireless programmer, physicians can take noninvasive readings on the implanted device and adjust therapy without the use of a wand. Guidant said the wireless system will save physicians and patients time during implant and at follow-up, with device interrogations that can be three times faster than Guidant's previous programmer.
Guidant plans to introduce these products in the U.S. during the fourth quarter of this year.
Upcoming Events
-
07May
-
14May
-
30May